Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of CC-99677 in Active Ankylosing Spondylitis
2019-004108-37Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ankylosing spondylitis (AS) comparing CC-99677 once daily with Placebo once daily (2 arms). Primary endpoint: ASAS20 response at week 12. Started Feb 2021; status: completed.
02
Drugs
gamcemetinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2019-004108-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004108-37.